|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500101553 |
|
最近更新日期: Date of Last Refreshed on: |
2025-04-27 08:27:28 |
|
注册时间: Date of Registration: |
2025-04-27 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
布比卡因脂质体用于剖宫产术后镇痛的最低有效剂量研究(MEC90) |
|
Public title: |
The study on the minimum effective dose (MEC90) of bupivacaine liposome for post-cesarean section analgesia. |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
布比卡因脂质体用于剖宫产术后镇痛的最低有效剂量研究(MEC90) |
|
Scientific title: |
The study on the minimum effective dose (MEC90) of bupivacaine liposome for post-cesarean section analgesia. |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张孟伟 |
研究负责人: |
张英 |
|
Applicant: |
Zhang Mengwei |
Study leader: |
Zhang Ying |
|
申请注册联系人电话: Applicant telephone: |
+86 152 8303 5745 |
研究负责人电话:
Study leader's |
+86 135 5172 0908 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2601958181@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
zhangying021210@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省泸州市龙马潭区春晖路182号 |
研究负责人通讯地址: |
四川省泸州市龙马潭区春晖路182号 |
|
Applicant address: |
182 Chunhui Road, Longmatan District, Luzhou City, Sichuan Province |
Study leader's address: |
182 Chunhui Road, Longmatan District, Luzhou City, Sichuan Province |
|
申请注册联系人邮政编码: Applicant postcode: |
646000 |
研究负责人邮政编码: Study leader's postcode: |
646000 |
|
申请人所在单位: |
西南医科大学附属中医医院 |
||
|
Applicant's institution: |
Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University |
||
|
研究负责人所在单位: |
西南医科大学附属中医医院 |
||
|
Affiliation of the Leader: |
Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY2025008 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
西南医科大学附属中医医院医学伦理审查委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Review Committee of the Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-03-06 00:00:00 | ||
|
伦理委员会联系人: |
贾强 |
||
|
Contact Name of the ethic committee: |
Jia Qiang |
||
|
伦理委员会联系地址: |
四川省泸州市龙马潭区春晖路182号 |
||
|
Contact Address of the ethic committee: |
182 Chunhui Road, Longmatan District, Luzhou City, Sichuan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 830 251 6312 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
西南医科大学附属中医医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省泸州市龙马潭区春晖路182号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
182 Chunhui Road, Longmatan District, Luzhou City, Sichuan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
四川省医学会肿瘤、麻醉等领域(恒瑞-一行)专项科研项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Sichuan Medical Association Special Research Projects in Oncology, Anesthesiology, and Other Fields (Hengrui-Yixing) |
||||||||||||||||||||||
|
研究疾病: |
术后疼痛 |
||||||||||||||||||||||
|
Target disease: |
Postsurgical pain |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
探究布比卡因脂质体用于剖宫产手术术后镇痛的临床疗效、安全性以及最佳使用剂量,从而进一步优化剖腹产手术术后多模式镇痛方案 |
||||||||||||||||||||||
|
Objectives of Study: |
To investigate the clinical efficacy, safety, and optimal dosage of liposomal bupivacaine for postoperative analgesia in cesarean section, thereby further optimizing the multimodal analgesia protocol following cesarean delivery |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.拟在西南医科大学附属中医医院接受择期剖宫产的患者 2.年龄在18 - 40岁之间 3.美国麻醉医师协会(ASA)分级I-II级 4.体重在60 - 80kg之间 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Patients scheduled to undergo elective cesarean section at the Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University. 2.Age between 18 and 40 years. 3.American Society of Anesthesiologists (ASA) physical status classification of I-II. 4.Body weight between 60 and 80 kg. |
||||||||||||||||||||||
|
排除标准: |
1. 拒绝参加研究 2. 对局部麻醉剂过敏 3. 既往存在神经病变 4. 凝血功能障碍(血小板应>= 80×10^9 /L) 5. 高危妊娠 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Refusing to participate in a study 2. Allergic to local anesthetics 3. Previous neuropathy 4. Coagulation dysfunction (platelets should be >= 80×10^9 /L) 5. High-risk pregnancy |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-08-01 00:00:00至 To 2026-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-05-07 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
神经阻滞实施者、随访人员以及病人为施盲对象 |
|
Blinding: |
The practitioners of nerve block, follow-up personnel, and patients are the subjects of blinding. |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |